Oncogenes are to lose control on signaling following mutation: Should we aim off target?

Molecular Biotechnology

Volumn 34, Issue 2, 2006, Pages 109-116

  Hornberg, Jorrit J ^a,c   Westerhoff, Hans V ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NV ORGANON   (Netherlands)

Author keywords

Cancer therapy; Control analysis; Drug target discovery; Kinase inhibitor; MAP kinase; Systems Biology

Indexed keywords

CONTROLLED DRUG DELIVERY; ENZYME KINETICS; LIVING SYSTEMS STUDIES; MUTAGENESIS; ONCOLOGY; TUMORS;

DRUG TARGET DISCOVERY; MUTATION; NONMUTATED GENES; ONCOGENES; SYSTEMS BIOLOGY;

GENES;

CONFERENCE PAPER; GENE CONTROL; GENE MUTATION; ONCOGENE; SIGNAL TRANSDUCTION;

HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; ONCOGENES; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 33845918111     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:34:2:109     Document Type: Conference Paper

References (22)

1. Cahill, D. P., Kinzler, K. W., Vogelstein, B., and Lengauer, C. (1999) Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9, M57-M60.
2. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
3. Vogelstein, B. and Kinzler, K. W. (2004) Cancer genes and the pathways they control. Nat. Med. 10, 789-799.
4. Mendelsohn, J. and Baselga, J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
5. Shawver, L. K., Slamon, D., and Ullrich, A. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123.
6. Giaccone, G. and Rodriguez, J. A. (2005) EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat. Clin. Pract. Oncol. 2, 554-561.
7. Sebolt-Leopold, J. S. and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947.
8. Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., and Lankelma, J. (2006) Cancer: a systems biology disease. Biosystems 83, 81-90.
9. Snoep, J. L. and Olivier, B. G. (2002) Java web simulation (JWS): a web based database of kinetic models. Mol. Biol. Rep. 29, 259-263.
10. Hornberg, J. J., Bruggeman, F. J., Binder, B., et al. (2005) Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS J. 272, 244-258.
11. Hornberg, J. J., Binder, B., Bruggeman, F. J., et al. (2005) Control of MAPK signalling: from complexity to what really matters. Oncogene 24, 5533-5542.
12. Lee, E., Salic, A., Kruger, R., et al. (2003) The roles of APC and axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biology 1, e10.
13. Ihekwaba, A. E., Broomhead, D. S., Grimley, R. L., et al. (2004) Sensitivity analysis of parameters controlling oscillatory signalling in the NF-kB pathway: the roles of IKK and IkBa. Syst. Biol. 1, 93-103.
14. Mendes, P. (1997) Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. Trends Biochem. Sci. 22, 361-363.
15. Kacser, H. and Burns, J. A. (1973) The control of flux. Symp. Soc. Exp. Biol. 27, 65-104.
16. Heinrich, R. and Rapoport, T. A. (1974) A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. Eur. J. Biochem. 42, 89-95.
17. Fell, D. A. (1997) Understanding the control of metabolism. Portland Press, London, UK.
18. Davies, H., Bignell, G. R., Cox, C., et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
19. Hoshino, R., Chatani, Y., Yamori, T., et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822.
20. Wan, P. T., Garnett, M. J., Roe, S. M., et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867.
21. Kahn, D. and Westerhoff, H. V. (1991) Control theory of regulatory cascades. J. Theor. Biol. 153, 255-285.
22. Solit, D. B., Garraway, L. A., Pratilas, C. A., et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362.